Our Pricing

Buy Mounjaro UK - Prescription Weight Loss Treatment

Published on: June 03, 2026

When you buy Mounjaro UK online pharmacy services like Cured Pharmacy offer transparent pricing from £135.00 free clinical consultations with UK-registered prescribers, and discreet next-day delivery. Mounjaro (tirzepatide) is a prescription-only weight loss injection licensed by the MHRA for adults with a BMI of 30 or above, or 27 with weight-related health conditions.

How Mounjaro Works for Weight Loss

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK for chronic weight management [1]. Unlike single-pathway treatments such as semaglutide, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. This dual action regulates blood sugar levels, reduces appetite, slows gastric emptying, and increases feelings of fullness after meals.

In the landmark SURMOUNT-1 trial, adults receiving the 15mg maintenance dose of tirzepatide achieved an average body weight reduction of 22.5% over 72 weeks, compared to 2.4% in the placebo group [1]. These results represent some of the most significant weight loss outcomes seen in clinical trials for pharmacological obesity treatment. The dual receptor mechanism appears to produce greater metabolic benefits than GLP-1 agonists alone, though individual results vary based on adherence to diet, exercise, and dosing schedules.

Mounjaro Dosing and Treatment Schedule

Mounjaro is administered as a once-weekly subcutaneous injection using a pre-filled KwikPen device. Treatment begins at a starting dose of 2.5mg weekly for the first four weeks, which serves as a tolerability phase rather than a therapeutic dose [2]. Your prescriber will then increase the dose in 2.5mg increments every four weeks, typically progressing through 5mg, 7.5mg, 10mg, 12.5mg, and up to a maximum maintenance dose of 15mg weekly.

This gradual dose escalation minimises gastrointestinal side effects such as nausea and diarrhoea, which are most common during the initial weeks of treatment. Most patients reach their maintenance dose within 20-24 weeks. The injection can be administered at any time of day, with or without meals, but should be taken on the same day each week for optimal consistency. If you miss a dose, it should be administered within four days; otherwise, skip the missed dose and resume your regular schedule.

Who Can Use Mounjaro?

Mounjaro is licensed in the UK for adults aged 18 and over with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [3]. It is not suitable for individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. A UK prescriber will assess your full medical history during your online consultation to determine suitability.

Mounjaro vs Wegovy: Comparing Weight Loss Injections

Both Mounjaro and Wegovy are once-weekly injectable treatments licensed by the MHRA for chronic weight management, but they work through different receptor mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that activates a single metabolic pathway, while Mounjaro's tirzepatide activates both GIP and GLP-1 receptors. In head-to-head trials, tirzepatide demonstrated superior weight loss outcomes compared to semaglutide at comparable doses [4].

The SURMOUNT-1 trial showed an average weight reduction of 22.5% with tirzepatide 15mg, compared to approximately 15% with semaglutide 2.4mg in the STEP trials [1][5]. Both medications share similar side effect profiles, predominantly gastrointestinal symptoms during the dose escalation phase. Wegovy may be preferred for patients who respond well to GLP-1 therapy alone or who have prior experience with liraglutide (Saxenda). Mounjaro may be more suitable for those seeking maximum weight loss potential, subject to prescriber assessment and individual tolerance.

Alternative Weight Loss Treatments Available

Beyond injectable GLP-1 therapies, UK patients have access to oral weight loss medications such as Orlistat, which works by blocking fat absorption in the digestive system. Orlistat is available in 120mg prescription strength or 60mg over-the-counter formulations (Alli, Orlos). While generally well-tolerated, Orlistat requires adherence to a low-fat diet to minimise gastrointestinal side effects and produces more modest weight loss (typically 5-10%) compared to injectable treatments. Your prescriber will recommend the most appropriate option based on your BMI, medical history, previous treatment responses, and personal preferences.

Common Side Effects and How to Manage Them

The most frequently reported side effects of Mounjaro are gastrointestinal in nature, including nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [2]. These symptoms typically occur during the initial weeks of treatment and dose escalation phases, affecting approximately 20-30% of patients in clinical trials. Most cases are mild to moderate in severity and resolve within a few days as the body adjusts to each new dose level.

To minimise gastrointestinal symptoms, eat smaller, more frequent meals throughout the day, avoid high-fat and spicy foods, stay well-hydrated, and take your injection at a consistent time each week. If nausea persists, your prescriber may recommend remaining at your current dose for an additional four weeks before escalating further. Serious but rare side effects include pancreatitis (severe abdominal pain radiating to the back), gallbladder problems, and hypoglycaemia in patients taking concurrent diabetes medications. Contact your prescriber immediately if you experience persistent severe abdominal pain, yellowing of the skin or eyes, or signs of an allergic reaction.

How to Buy Mounjaro UK from Cured Pharmacy

To buy Mounjaro UK through Cured Pharmacy, start by completing our free online consultation, which takes under three minutes. You'll answer questions about your medical history, current medications, weight management goals, and any previous experience with weight loss treatments. A UK-registered prescriber from our clinical team will review your assessment within 24 hours and determine whether Mounjaro is safe and appropriate for you.

If approved, your prescription is sent electronically to our GPhC-registered pharmacy (9012511), where superintendent pharmacist Tarun Kumar (GPhC 2233073) and our dispensing team prepare your medication. Mounjaro is dispatched in 100% discreet packaging via next-day delivery to any UK address. Pricing is transparent and displayed upfront at £124.99 before you begin your consultation—there are no hidden fees or surprise charges. All Mounjaro pens supplied are genuine UK-licensed medicines sourced directly from licensed wholesalers.

Ongoing Support and Prescription Renewals

Weight loss treatment with Mounjaro is a long-term commitment, typically lasting 6-12 months or longer depending on your goals and clinical response. Cured Pharmacy provides ongoing support throughout your treatment journey, with repeat prescription services and access to our clinical team for any questions or concerns. Your prescriber will monitor your progress at regular intervals and may adjust your dose or recommend alternative treatments if you experience intolerable side effects or insufficient weight loss after 16-20 weeks at maintenance dose.

Clinical Evidence: What the Trials Show

The efficacy of tirzepatide for weight management has been established through the SURMOUNT clinical trial programme, which enrolled over 5,000 adults with obesity or overweight across multiple international sites [1]. SURMOUNT-1, the largest trial, demonstrated dose-dependent weight loss with tirzepatide 5mg (15% average reduction), 10mg (19.5% average reduction), and 15mg (22.5% average reduction) over 72 weeks. Approximately 63% of participants on the highest dose achieved at least 20% body weight reduction, and 40% achieved at least 25% reduction.

Beyond weight loss, tirzepatide produced significant improvements in cardiometabolic risk factors including waist circumference, blood pressure, lipid profiles, and markers of insulin resistance [6]. In patients with type 2 diabetes, tirzepatide also improved glycaemic control, with many achieving HbA1c levels below 7% without requiring additional diabetes medications. These comprehensive metabolic benefits extend beyond simple weight reduction and may contribute to long-term cardiovascular and metabolic health improvements, though long-term outcome studies are ongoing.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Eli Lilly and Company. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/14513 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating obesity (TA1003). NICE Technology Appraisal Guidance. https://www.nice.org.uk/guidance/ta1003 [accessed 13 August 2026]
4. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
6. Garvey, W. T., et al. (2023). Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. The Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to diet, exercise, and prescribed treatment protocols.